BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krzyżek P, Grande R. Transformation of Helicobacter pylori into Coccoid Forms as a Challenge for Research Determining Activity of Antimicrobial Substances. Pathogens 2020;9:E184. [PMID: 32143312 DOI: 10.3390/pathogens9030184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhong Z, Wang X, Li J, Zhang B, Yan L, Xu S, Chen G, Gao H. A study on the diagnosis of the Helicobacter pylori coccoid form with artificial intelligence technology. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1008346] [Reference Citation Analysis]
2 Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 2022. [PMID: 34988937 DOI: 10.1007/s42770-021-00675-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
3 Silvan JM, Martinez-rodriguez AJ. Modulation of inflammation and oxidative stress in Helicobacter pylori infection by bioactive compounds from food components. Current Advances for Development of Functional Foods Modulating Inflammation and Oxidative Stress 2022. [DOI: 10.1016/b978-0-12-823482-2.00029-7] [Reference Citation Analysis]
4 Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Spiegel M, Krzyżek P, Dworniczek E, Adamski R, Sroka Z. In Silico Screening and In Vitro Assessment of Natural Products with Anti-Virulence Activity against Helicobacter pylori. Molecules 2021;27:20. [PMID: 35011255 DOI: 10.3390/molecules27010020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Senchukova MA, Tomchuk O, Shurygina EI. Helicobacter pylori in gastric cancer: Features of infection and their correlations with long-term results of treatment. World J Gastroenterol 2021;27:6290-305. [PMID: 34712033 DOI: 10.3748/wjg.v27.i37.6290] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
7 Alexander SM, Retnakumar RJ, Chouhan D, Devi TNB, Dharmaseelan S, Devadas K, Thapa N, Tamang JP, Lamtha SC, Chattopadhyay S. Helicobacter pylori in Human Stomach: The Inconsistencies in Clinical Outcomes and the Probable Causes. Front Microbiol 2021;12:713955. [PMID: 34484153 DOI: 10.3389/fmicb.2021.713955] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
8 Krzyżek P. Toxin-Antitoxin Systems - A New Player in Morphological Transformation of Antibiotic-Exposed Helicobacter pylori? Front Cell Infect Microbiol 2021;11:670677. [PMID: 33981631 DOI: 10.3389/fcimb.2021.670677] [Reference Citation Analysis]
9 Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT, Sáez K, García-Cancino A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021;10:382. [PMID: 33806815 DOI: 10.3390/pathogens10030382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Krzyżek P, Migdał P, Paluch E, Karwańska M, Wieliczko A, Gościniak G. Myricetin as an Antivirulence Compound Interfering with a Morphological Transformation into Coccoid Forms and Potentiating Activity of Antibiotics against Helicobacter pylori. Int J Mol Sci 2021;22:2695. [PMID: 33800082 DOI: 10.3390/ijms22052695] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Hebel-Gerber S, García-Cancino A, Urbina A, Simirgiotis MJ, Echeverría J, Bustamante-Salazar L, Sáez-Carrillo K, Alarcón J, Pastene-Navarrete E. Chilean Rhubarb, Gunnera tinctoria (Molina) Mirb. (Gunneraceae): UHPLC-ESI-Orbitrap-MS Profiling of Aqueous Extract and its Anti-Helicobacter pylori Activity. Front Pharmacol 2020;11:583961. [PMID: 33708110 DOI: 10.3389/fphar.2020.583961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Nowicka J, Piątkowska E. Small Colony Variants – The Cause Of Chronic Infections. Postępy Mikrobiologii - Advancements of Microbiology 2021;60:183-194. [DOI: 10.21307/pm-2021.60.3.14] [Reference Citation Analysis]
13 Domanovich-Asor T, Motro Y, Khalfin B, Craddock HA, Peretz A, Moran-Gilad J. Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in Helicobacter pylori. Microorganisms 2020;9:E2. [PMID: 33374988 DOI: 10.3390/microorganisms9010002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Krzyżek P, Grande R, Migdał P, Paluch E, Gościniak G. Biofilm Formation as a Complex Result of Virulence and Adaptive Responses of Helicobacter pylori. Pathogens 2020;9:E1062. [PMID: 33353223 DOI: 10.3390/pathogens9121062] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
15 Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm. Int J Mol Sci 2020;21:E9507. [PMID: 33327555 DOI: 10.3390/ijms21249507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Grande R, Puca V, Muraro R. Antibiotic resistance and bacterial biofilm. Expert Opin Ther Pat 2020;30:897-900. [PMID: 32985275 DOI: 10.1080/13543776.2020.1830060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
17 Krzyżek P, Paluch E, Gościniak G. Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori. Antibiotics (Basel) 2020;9:E658. [PMID: 33007899 DOI: 10.3390/antibiotics9100658] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]